Approval of bortezomib has validated ubiquitin-proteasome pathway as an important target
for treatment of haematological malignancies. However, clinical shortcomings of bortezomib …

The ubiquitin-proteasome proteolytic pathway plays a major role in selective protein
degradation and regulates various cellular events including cell cycle progression …

Natural products continue to be a source of inspiration for chemists and biologists alike. The
search for biologically active natural products has provided troves of information about …

Natural products serve as a main resource for drug discovery. The ubiquitin-proteasome
system (UPS) is one of the primary intracellular protein degradation systems, which is …

The ubiquitin-proteasome system plays a critical role in selective protein degradation and
regulates almost all cellular events such as cell cycle progression, signal transduction, cell …

Background: The proteasome is the major proteolytic site on the eukaryotic cell, degrading
most of its short-lived or misfolded polypeptides. The ubiquitin-proteasome pathway has …

In the past 15 years, the proteasome has been validated as an anti-cancer drug target and
20S proteasome inhibitors (such as bortezomib and carfilzomib) have been approved by the …

The ubiquitin-mediated degradation of proteins in numerous cellular processes, such as
turnover and quality control of proteins, cell cycle and apoptosis, transcription and cell …

The discovery of the proteasome in the late 80's as the core protease of what will be then
called the ubiquitin–proteasome system, rapidly followed by the development of specific …

The search for proteasome inhibitors began fifteen years ago. These inhibitors proved to be
powerful tools for investigating many important cellular processes regulated by the ubiquitin …